Population pharmacokinetics and exposure-response relationship of trastuzumab and bevacizumab in early-stage breast cancer

Autor:	A, Petitcollin, N, Azzopardi, J Y, Pierga, D, Ternant, I, Navarro-Teulon, C, Desvignes, M A, Mouret-Reynier, B, Coudert, G, Paintaud
Rok vydání:	2020
Předmět:	Adult Receptor ErbB-2 Breast Neoplasms Docetaxel Middle Aged Trastuzumab Models Biological Bevacizumab Antineoplastic Agents Immunological Area Under Curve Antineoplastic Combined Chemotherapy Protocols Humans Drug Interactions Female Aged Half-Life Neoplasm Staging
Zdroj:	European journal of clinical pharmacology. 77(12)
ISSN:	1432-1041
Popis:	To describe the sources of interindividual variability of bevacizumab and trastuzumab pharmacokinetics in early-stage breast cancer, and to study the relationship between exposure and both early clinical response and specific adverse events.Patients (n = 86) received 6 cycles of docetaxel + trastuzumab. Early tumour response was assessed by determination of the maximum standard uptake value (SUVA two-compartment model described the pharmacokinetics of both antibodies satisfactorily. Their central volume of distributions (Vc) increased with body surface area and their elimination half-lives were shorter (~14 days) than previously reported (~26-28 days). There was a time-dependent increase in trastuzumab Vc, positively correlated to baseline SUVTumour uptake as assessed by SUV
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::e0e87f60aeae5bd13e1274034d1d90d6 https://pubmed.ncbi.nlm.nih.gov/34245336 Zobrazit plný text záznamu Full text from SpringerLink